Covista (CVSA) is back in focus after expanding its healthcare AI credentials with Google Cloud to all five institutions and outlining plans to pilot a fully integrated, AI powered classroom experience later this year.

That partnership news lands at a time when Covista’s share price, now at $112.39, shows a mixed picture, with a 4.42% 1 day share price return but a softer 30 day share price return of 1.94%, while long term total shareholder returns over three and five years remain very strong.

If healthcare AI is on your radar, this is a good moment to widen your search and check out 32 healthcare AI stocks

With Covista trading at $112.39, sitting on strong multi year total shareholder returns and a value score of 6, plus a sizeable gap to the US$153.75 analyst target, is there still a buying opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 26.7% Undervalued

On the widely followed narrative, Covista’s fair value sits at $153.25 against the current $112.39 share price, with that gap built on detailed earnings and revenue projections.

Persistent health care workforce shortages in nursing, medicine and behavioral health create a structural need for large scale training capacity, which can support sustained demand for Covista's programs and underpin revenue growth.

Want to understand why this narrative supports a higher fair value? It leans on steady revenue gains, firmer profit margins and a richer earnings multiple tied to those targets.

Result: Fair Value of $153.25 (UNDERVALUED)

However, this upside story can be challenged if healthcare labor shortages ease faster than expected, or if tighter student lending rules start to curb enrollment demand.

Next Steps

With sentiment leaning positive but risks still on the table, this is a moment to review the numbers yourself and decide where you stand. To see what the market is optimistic about, take a closer look at the 5 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might suit your goals even better, so consider adding a few more ideas to your radar.

• Target steadier opportunities by checking companies in the 73 resilient stocks with low risk scores that may better match your comfort with volatility.
• Hunt for quality at compelling prices with the 53 high quality undervalued stocks and see which businesses currently trade below their assessed worth.
• Spot earlier stage potential by scanning the 24 elite penny stocks with strong financials where smaller names may offer different risk and reward profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.